drugset / Trial / NCT00555139

A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder

NCT00555139

Phase 1 Completed 35 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo

Timeline

Start
2007-03-27
Primary completion
2008-01-10
Completion
2008-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule 0.25 mg
Subject EMICERFONT Small molecule 100 mg
Subject VERUCERFONT Small molecule 200 mg

Indications